The company said consolidated net sales for the 3 months ended June 30, 2024 decreased $51.7 million (6.9%) from the same period a year earlier. It cited lower sales of certain high-value products at Proprietary Products, due to customer inventory management, as the reason for the decline in that segment's net sales.

1. 01

   The company said consolidated net sales for the 3 months ended June 30, 2024 decreased $51.7 million (6.9%) from the same period a year earlier. It cited lower sales of certain high-value products at Proprietary Products, due to customer inventory management, as the reason for the decline in that segment's net sales.

2. 02

   West Pharmaceutical Services said consolidated gross profit for Q2 2024 decreased $61.4 million (21.1%) and consolidated operating profit decreased $56.3 million (30.8%). It cited lower plant absorption from reduced customer demand and an unfavorable product mix as factors behind the decline in Proprietary Products gross profit margin.

3. 03

   The company said net cash provided by operating activities for the first half of 2024 (6 months) decreased $24.1 million, and net cash used in financing activities increased $241.5 million. It also said it repurchased 1,239,015 shares of its common stock for $454.1 million during the same period.

4. 04

   The company said that as of June 30, 2024, there were no outstanding borrowings under its Credit Facility and the available borrowing capacity was $497.6 million. The company also said that on the same date, its cash and cash equivalents included $140.9 million held by U.S. subsidiaries and $305.3 million held by subsidiaries outside the U.S.

Key figures

Quarter ended June 30, 2024

Revenue

$702M

Operating income

$126M

Net income

$111M

EPS

$1.51

Gross profit

$230M

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.